Adjuvant Nivolumab in Esophageal Cancer - A New Standard of Care
N Engl J Med
.
2021 Apr 1;384(13):1269-1271.
doi: 10.1056/NEJMe2101983.
Author
David H Ilson
1
Affiliation
1
From the Breast and Imaging Center, Memorial Sloan Kettering Cancer Center, New York.
PMID:
33789017
DOI:
10.1056/NEJMe2101983
No abstract available
Publication types
Editorial
Comment
MeSH terms
Esophageal Neoplasms* / drug therapy
Esophagogastric Junction
Humans
Nivolumab / adverse effects
Standard of Care
Stomach Neoplasms*
Substances
Nivolumab